证券代码：300642 证券简称：透景生命 公告编号：2025-042 上海透景生命科技股份有限公司 关于部分股票期权注销完成和部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"） 本次注销的股票期权涉及 54 人，注销的股票期权数量共计 1,661,400 份。其中， 2020 年股票期权与限制性股票激励计划股票期权（透景 JLC1）594,000 份，2023 年股票期权与限制性股票激励计划股票期权（透景 JLC2）1,067,400 份。 2、公司本次回购注销的限制性股票涉及 54 人，回购注销的股份数量共计 465,900 股，占回购注销前公司总股本 163,021,941 股的 0.2858%。其中，2020 年股票期权与限制性股票激励计划限制性股票的回购价格为 14.03 元/股，2023 年股票期权与限制性股票激励计划限制性股票的回购价格为 10.65 元/股，本次 限制性股票回购总金额为 5,415,093 元。 3、截至本公告披露日，公 ...

Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

Core Viewpoint - The company and its wholly-owned subsidiary, Shanghai Toukang Diagnostic Technology Co., Ltd., have recently received acceptance for their medical device registration applications from the Shanghai Municipal Drug Administration, which includes seven products across various diagnostic fields [1] Group 1: Product Registration - The accepted products include carcinoembryonic antigen, cytokeratin 19 fragment, neuron-specific enolase, squamous cell carcinoma antigen, gastrin-releasing peptide precursor assay kit (flow fluorescence method), 25-hydroxyvitamin D assay kit (chemiluminescent immunoassay), anti-double-stranded DNA antibody, anti-C1q antibody, anti-M2-3E antibody, anti-nucleosome antibody, and anti-phospholipid syndrome IgA antibody assay kit (flow fluorescence method) [1] - These products cover tumor detection, metabolic detection, and autoimmune detection, which will help enrich the company's product line, meet market demand, and enhance market competitiveness [1] Group 2: Approval Process - The current stage of the approval process is the acceptance of the registration application, with subsequent steps including technical review, administrative approval, and issuance of the license [1] - The acceptance of these product registration applications will not have an impact on the company's or Toukang Diagnostic's recent performance [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-041 上海透景生命科技股份有限公司 关于申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"）及全 资子公司上海透景诊断科技有限公司（以下简称"透景诊断"或"全资子公司"） 申报的医疗器械注册申请于近期获得了上海市药品监督管理局的受理，具体情况 如下： | 序号 | 产品名称 | 注册分类 | 申请人 | 预期用途 | | --- | --- | --- | --- | --- | | | 癌胚抗原、细胞角蛋白 | | | 本试剂盒用于定量检测人血清中 | | | 19 片段、神经元特异性 | | | CEA、CYFRA21-1、NSE、SCC 和 ProGRP | | | 烯醇化酶、鳞状上皮细 | 第二类体 | 透景 | 的浓度。用于对肺癌患者的治疗监 | | 1 | | 外诊断试 | | | | | 胞癌抗原、胃泌素释放 | 剂 | 生命 | 测，不能作为恶性肿瘤早期诊断或确 | | | 肽前体测定试剂盒 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-040 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司 关于回购公司股份的进展公告 二、其他说明 公司后续将根据市场情况在本次回购股份方案规定的回购期限内择机做出 回购决策并予以实施，并将在回购期间根据相关法律、法规和规范性文件的规定 及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海透景生命科技股份有限公司 董 事 会 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 召开第四届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。本次回购的股份用于股权激励或员工持股计划，用于回购股份的 资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回 购股份价格不超过 16.00 元/股（含），实施期限为自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容请详见公司分别于 2025 年 4 月 8 日、 2025 年 4 月 14 日在巨潮资讯网（www. ...

证券代码：300642 证券简称：透景生命 公告编号：2025-039 上海透景生命科技股份有限公司 关于特定股东减持公司股份的预披露公告 特定股东上海荣振投资集团有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 持有上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"） 股份 2,364,895 股（占公司总股本注1比例 1.47%）的股东上海荣振投资集团有限 公司（以下简称"荣振投资"或"股东"）自本公告披露之日起 3 个交易日后的 3 个月内以证券交易所集中竞价交易方式或大宗交易方式减持公司股份不超过 1,150,000 股（占公司总股本 0.71%）。 公司于近日收到股东荣振投资出具的《关于计划减持公司股份的告知函》， 现将有关内容公告如下： 一、股东基本情况 | 股东名称 | 持股数量（股） | 占公司总股本的比例 | | --- | --- | --- | | 上海荣振投资集团有限公司 | 2,364,895 | 1.47% | 减持期间：自本公告披露日起 3 个交易 ...

透景生命（300642）公告，持有公司1.47%股份的股东上海荣振投资集团有限公司计划自公告披露日起 3个交易日后的3个月内，通过证券交易所集中竞价交易或大宗交易方式减持不超过115万股，占公司总 股本0.71%。 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-038 上海透景生命科技股份有限公司 关于持股 5%以上股东股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注 2：上述比例均按照四舍五入保留两位小数计算，下同。若出现合计数与各分项数据 之和尾数不符的，均为四舍五入原因所致。 2、本次股份质押基本情况 | 股东 | 是否为控股股东 | 本次质押数 | 占其所 | 占公司 | 是否 | 是否为 | 质押起 | 质押到 | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 量（股） | 持股份 | 总股本 | 为限 | 补充质 | 始日 | 期日 | | 质权人 | 用途 | | | 其一致行动人 | | 比例 | 比例 | 售股 | 押 | | | | 上海浦东 | | | 凌飞 | | | | | | | 2025 年 | 2028 | 年 | 发展银行 | 自身 | | ...

Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., focuses on the research, production, and sales of in vitro diagnostic products under its own brand [1] - Main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - Net profit for the same period was 471,700 yuan, showing a significant year-on-year increase of 110.51% [1] - The gross profit margin was reported at 63.66% [1] Market Position - As of May 27, the company's stock closed at 14.02 yuan, with a PE ratio of 57.87 times [1] - The total market capitalization of the company is 2.286 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 49.11 times, with a median of 35.89 times, placing the company at the 93rd position in the industry ranking [1][2] Institutional Holdings - As of Q1 2025, five institutions hold shares in the company, with a total of 28.0388 million shares valued at 403 million yuan [1]

Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] - The main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported operating revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - The net profit for the same period was 471,700 yuan, showing a year-on-year increase of 110.51% [1] - The gross profit margin was reported at 63.66% [1] Market Position - As of May 22, the company's stock closed at 13.8 yuan, down 1.64%, with a rolling price-to-earnings (PE) ratio of 56.96 times [1] - The total market capitalization is 2.25 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 48.71 times, with a median of 35.37 times, placing the company at the 93rd position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 17,040, a decrease of 590 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]